^
    3d
    Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report. (PubMed, Int J Hematol)
    JTT may enhance the efficacy of T cell-redirecting immunotherapies in RRMM by promoting cytotoxic T cell expansion. These findings warrant further investigation into the use of JTT as an adjunct to improve outcomes in patients with EMD.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Elrexfio (elranatamab-bcmm)
    4d
    CREATT: Multi-center, Observational Study of Teclistamab or Talquetamab in The Treatment of Multiple Myeloma Patients in China (ChiCTR2500112479)
    P4, N=200, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P4 trial
    |
    Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    6d
    BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Medical College of Wisconsin | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    |
    Lynozyfic (linvoseltamab-gcpt)
    8d
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Trial primary completion date: Oct 2041 --> Jan 2042
    Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    8d
    MajesTEC-1: A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=194, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Nov 2025 --> Aug 2025
    Trial primary completion date • First-in-human
    |
    Tecvayli (teclistamab-cqyv)
    11d
    Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection. (PubMed, Nephrol Dial Transplant)
    We furthermore discuss genetically engineered CD38 knock-out multitarget natural killer cells, expressing anti-B cell maturation antigen (BCMA) CAR, IL-15RF and hnCD16, administered in combination with daratumumab (anti-CD38) in this context...Likewise, we hypothesize the use of bi-specific T cell engagers such as CD19 blinatumomab or BCMA teclistamab for the treatment of AMR...In summary, anti-CD38 antibodies currently constitute the drug class with the strongest evidence for AMR treatment. To date, most CD38 antibodies have been shown to be safe, even after several years of administration in patients with multiple myeloma.
    Journal
    |
    IL6 (Interleukin 6) • CD40LG (CD40 ligand)
    |
    Blincyto (blinatumomab) • Darzalex (daratumumab) • Tecvayli (teclistamab-cqyv)
    11d
    DREAMM-20: A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (clinicaltrials.gov)
    P1/2, N=153, Recruiting, GlaxoSmithKline | Phase classification: P1 --> P1/2 | N=55 --> 153
    Phase classification • Enrollment change
    |
    dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)
    12d
    A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2042 --> Oct 2041
    Enrollment open • Trial primary completion date • Adverse events
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • etentamig intravenous (ABBV-383 IV)
    14d
    Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. (PubMed, Front Oncol)
    Neutrophil recovery occurred by day +10, transfusion independence by day +19, and hematologic recovery allowed elranatamab resumption without recurrence of severe cytopenia. This case demonstrates the potential utility of SCB for managing persistent cytopenias after T-cell-redirecting therapies and supports the importance of early stem cell collection.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Elrexfio (elranatamab-bcmm)
    14d
    A Study of Cizutamig for Patients With Ulcerative Colitis (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Ruijin Hospital
    New P1 trial
    14d
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    15d
    OPTec: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (clinicaltrials.gov)
    P2, N=100, Recruiting, SCRI Development Innovations, LLC | N=75 --> 100
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Actemra IV (tocilizumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)